M&A Deal Summary

Medicure Acquires Apicore

On November 18, 2016, Medicure acquired life science company Apicore

Acquisition Highlights
  • This is Medicure’s 1st transaction in the Life Science sector.
  • This is Medicure’s 1st transaction in the United States.
  • This is Medicure’s 1st transaction in New Jersey.

M&A Deal Summary
Date 2016-11-18
Target Apicore
Sector Life Science
Buyer(s) Medicure
Deal Type Add-on Acquisition

Target

Apicore

Somerset, New Jersey, United States
Apicore, Inc. is a developer and manufacturer of specialty Active Pharmaceutical Ingredients ("APIs") and pharmaceuticals, including over 15 Abbreviated New Drug Applications ("ANDAs"), one of which, is partnered with Medicure. Apicore manufactures over 100 different API's, including over 35 for which Drug Master Files have been submitted to the FDA and 12 that are approved for commercial sale in the U.S. by customers of Apicore.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Medicure

Winnipeg, Manitoba, Canada
Category Company
Founded 1997
Sector Life Science
Revenue 22M CAD (2023)
DESCRIPTION

Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market. The Company’s current focus is in the area of acute cardiovascular care, a market served by its commercial product, AGGRASTAT (tirofiban HCl). Medicure was founded in 1997 and is based in Winnipeg, Manitoba.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 2
State (New Jersey) 1 of 1
Country (United States) 1 of 3
Year (2016) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-09-30 Zypitamag

United States

Zypitamag is an HMG-CoA reductase inhibitor indicated for adult patients with primary hyperlipidemia or mixed dyslipidemia as adjunctive therapy to diet, to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C)

Buy $7M
Mergr

Product

Company

Legal